Adenosine receptor agonists for promotion of dermal wound healing.

Wound healing is a dynamic and complex process that involves a well-coordinated, highly regulated series of events including inflammation, tissue formation, revascularization and tissue remodeling. However, this orderly sequence is impaired in certain pathophysiological conditions such as diabetes mellitus, venous insufficiency, chronic glucocorticoid use, aging and malnutrition. Together with proper wound care, promotion of the healing process is the primary objective in the management of chronic poorly healing wounds. Recent studies have demonstrated that A(2A) adenosine receptor agonists promote wound healing in normal and diabetic animals and one such agonist, Sonedenoson, is currently being evaluated as a prospective new therapy of diabetic foot ulcers. We will review the mechanisms by which adenosine receptor activation affects the function of the cells and tissues that participate in wound healing, emphasizing the potential beneficial impact of adenosine receptor agonists in diabetic impaired healing.

[1]  E. Deitch,et al.  Adenosine inhibits IL-12 and TNF-a production via adenosine A 2 a receptor-dependent and independent mechanisms , 2000 .

[2]  D. Gingras,et al.  VEGF increases the fibrinolytic activity of endothelial cells within fibrin matrices: involvement of VEGFR-2, tissue type plasminogen activator and matrix metalloproteinases. , 2007, Thrombosis research.

[3]  B. Cronstein,et al.  Adenosine A2A Receptor Agonists Promote More Rapid Wound Healing Than Recombinant Human Platelet–Derived Growth Factor (Becaplermin Gel) , 2002, Inflammation.

[4]  T. Skalak,et al.  Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation. , 2001, American journal of physiology. Heart and circulatory physiology.

[5]  M. Pittelkow,et al.  Adenosine and adenine nucleotides inhibit the autonomous and epidermal growth factor-mediated proliferation of cultured human keratinocytes. , 1995, The Journal of investigative dermatology.

[6]  P. Rhee,et al.  Cyclopentyladenosine improves cell proliferation, wound healing, and hair growth. , 1999, The Journal of surgical research.

[7]  B. Cronstein,et al.  Adenosine A2A Receptor Stimulation Increases Angiogenesis by Down-Regulating Production of the Antiangiogenic Matrix Protein Thrombospondin 1 , 2005, Molecular Pharmacology.

[8]  C. Taylor,et al.  Neutrophil-derived 5′-Adenosine Monophosphate Promotes Endothelial Barrier Function via CD73-mediated Conversion to Adenosine and Endothelial A2B Receptor Activation , 1998, The Journal of experimental medicine.

[9]  D. Erlinge,et al.  Extracellular Nucleotides ATP and UTP Induce a Marked Acute Release of Tissue-type Plasminogen Activator In Vivo in Man , 2001, Thrombosis and Haemostasis.

[10]  E. Kruithof,et al.  Synergistic Induction of t-PA by Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor and Localization of t-PA to Weibel-Palade Bodies in Bovine Microvascular Endothelial Cells , 2001, Thrombosis and Haemostasis.

[11]  Thomas A. Mustoe, MD, FACS,et al.  Pharmacologic enhancement of wound healing. , 1995, Annual review of medicine.

[12]  B. Cronstein,et al.  Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. , 1998, The Journal of clinical investigation.

[13]  Gilles Clermont,et al.  Agent-based model of inflammation and wound healing: insights into diabetic foot ulcer pathology and the role of transforming growth factor-beta1. , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[14]  Z. Ge,et al.  Adenosine Inhibits Tumor Necrosis Factor-α Release from Mouse Peritoneal Macrophages via A2A and A2B but Not the A3 Adenosine Receptor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[15]  B. Cronstein,et al.  The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. , 1990, The Journal of clinical investigation.

[16]  W. Jeffcoate,et al.  A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes , 2008, Diabetes/metabolism research and reviews.

[17]  L. Chiriboga,et al.  Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. , 2008, The American journal of pathology.

[18]  T. Adair.  Growth regulation of the vascular system: an emerging role for adenosine. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[19]  R. Tarnuzzer,et al.  Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. , 1999, Circulation research.

[20]  B. Cronstein,et al.  Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis , 2006, Arthritis research & therapy.

[21]  J. G. van der Hoeven,et al.  The effect of adenosine receptor agonists on cytokine release by human mononuclear cells depends on the specific Toll-like receptor subtype used for stimulation. , 2006, Cytokine.

[22]  R. Helme,et al.  Sensory peptides as neuromodulators of wound healing in aged rats. , 1996, The journals of gerontology. Series A, Biological sciences and medical sciences.

[23]  M. Postow,et al.  Tumor necrosis factor-alpha prevents desensitization of Galphas-coupled receptors by regulating GRK2 association with the plasma membrane. , 2006, Molecular pharmacology.

[24]  R. Kimberly,et al.  Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. , 1993, Journal of immunology.

[25]  B. Cronstein,et al.  Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. , 2007, The American journal of pathology.

[26]  Beverly H. Koller,et al.  Disruption of the A3 Adenosine Receptor Gene in Mice and Its Effect on Stimulated Inflammatory Cells* , 2000, The Journal of Biological Chemistry.

[27]  K. Woo,et al.  The biology of chronic foot ulcers in persons with diabetes , 2008, Diabetes/metabolism research and reviews.

[28]  Rebecca J Blatt,et al.  Adenosine Receptor Activation Promotes Angiogenesis and Release of Vegf from 1 A , 2007 .

[29]  T. Voyno-Yasenetskaya,et al.  Differential Expression of Adenosine Receptors in Human Endothelial Cells: Role of A2B Receptors in Angiogenic Factor Regulation , 2002, Circulation research.

[30]  M. Postow,et al.  Tumor Necrosis Factor-α Prevents Desensitization of Gαs-Coupled Receptors by Regulating GRK2 Association with the Plasma Membrane , 2006, Molecular Pharmacology.

[31]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[32]  B. Cronstein,et al.  Role of P1 Receptors in Inflammation , 2001 .

[33]  M. Sitkovsky.  Extracellular purines and their receptors in immunoregulation. Review of recent advances. , 1998, Nihon Ika Daigaku zasshi.

[34]  B. Fredholm,et al.  Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. , 2001, Biochemical pharmacology.

[35]  J. Montani,et al.  Adenosine infusion increases plasma levels of VEGF in humans , 2005, BMC Physiology.

[36]  J. Emeis,et al.  Adenosine 3':5'-cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells. , 1998, Thrombosis and haemostasis.

[37]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[38]  I. Biaggioni,et al.  Hypoxia Modulates Adenosine Receptors in Human Endothelial and Smooth Muscle Cells Toward an A2B Angiogenic Phenotype , 2004, Hypertension.

[39]  B. Cronstein,et al.  Th1 Cytokines Regulate Adenosine Receptors and Their Downstream Signaling Elements in Human Microvascular Endothelial Cells 1 , 2003, The Journal of Immunology.

[40]  B. Cronstein,et al.  Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. , 2002, The American journal of pathology.

[41]  P. Fishman,et al.  Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. , 2005, The Journal of rheumatology.

[42]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. , 1993, The Journal of clinical investigation.

[43]  M. Braun,et al.  Purinergic substances promote murine keratinocyte proliferation and enhance impaired wound healing in mice , 2006, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[44]  S. Colgan,et al.  Crucial Role for Ecto-5′-Nucleotidase (CD73) in Vascular Leakage during Hypoxia , 2004, The Journal of experimental medicine.

[45]  A. Bitto,et al.  Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[46]  S. Mousa,et al.  Signaling through JAM-1 and αvβ3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and αvβ3 complex , 2003 .

[47]  G. Firestein,et al.  Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-D-aspartate receptors. , 1996, The Journal of clinical investigation.

[48]  Geoffrey Burnstock,et al.  Purinergic signalling , 2012, Acta physiologica.

[49]  Pál Pacher,et al.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases , 2006, Nature Reviews Drug Discovery.

[50]  B. Fredholm,et al.  Signalling from adenosine receptors to mitogen-activated protein kinases. , 2003, Cellular signalling.

[51]  G. Clermont,et al.  Agent‐based model of inflammation and wound healing: insights into diabetic foot ulcer pathology and the role of transforming growth factor‐β1 , 2007 .

[52]  D. Schrier,et al.  The effects of (R)-N-(1-methyl-2-phenylethyl) adenosine (L-PIA), a standard A1-selective adenosine agonist on rat acute models of inflammation and neutrophil function , 1991, Agents and Actions.

[53]  M. Huijberts,et al.  Neurovascular control and neurogenic inflammation in diabetes , 2008, Diabetes/metabolism research and reviews.

[54]  G. Firestein,et al.  Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. , 1994, Arthritis and rheumatism.

[55]  E. Levin,et al.  Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. , 1988, The Journal of biological chemistry.

[56]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[57]  L. Lund,et al.  Plasminogen and wound healing , 1996, Nature Medicine.

[58]  R. G. Sitrin,et al.  Adenosine receptors on rabbit alveolar macrophages: binding characteristics and effects on cellular function. , 1987, The Journal of laboratory and clinical medicine.

[59]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[60]  M. Mirabet,et al.  IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. , 1999, Journal of immunology.

[61]  B S Khakh,et al.  International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. , 2001, Pharmacological reviews.

[62]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[63]  B. Cronstein,et al.  Wound Healing Is Accelerated by Agonists of Adenosine A2 (Gα s-linked) Receptors , 1997, The Journal of experimental medicine.

[64]  B. Cronstein,et al.  Adenosine A2A Receptor Blockade or Deletion Diminishes Fibrocyte Accumulation in the Skin in a Murine Model of Scleroderma, Bleomycin-induced Fibrosis , 2008, Inflammation.

[65]  Vincent Falanga,et al.  Wound healing and its impairment in the diabetic foot , 2005, The Lancet.

[66]  W. Buurman,et al.  Differential regulatory effects of adenosine on cytokine release by activated human monocytes. , 1994, Journal of immunology.

[67]  L. Rodríguez-Mañas,et al.  The deleterious effect of high concentrations of D-glucose requires pro-inflammatory preconditioning , 2008, Journal of hypertension.

[68]  D. S. Mcleod,et al.  Adenosine stimulates canine retinal microvascular endothelial cell migration and tube formation. , 1998, Current eye research.

[69]  I. Biaggioni,et al.  Mast Cell–Mediated Stimulation of Angiogenesis: Cooperative Interaction Between A2B and A3 Adenosine Receptors , 2003, Circulation research.

[70]  T. Pawełczyk,et al.  Diabetes-induced alterations of adenosine receptors expression level in rat liver. , 2007, Experimental and molecular pathology.

[71]  H. Yee,et al.  Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. , 2002, The American journal of pathology.

[72]  L. Lund,et al.  Impaired wound healing in mice with a disrupted plasminogen gene , 1996, Nature Medicine.

[73]  M. Pepper.  Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[74]  S. Werner,et al.  Regulation of wound healing by growth factors and cytokines. , 2003, Physiological reviews.

[75]  G. Schettini,et al.  Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: involvement of A2 purinergic receptor subtypes. , 1999, Life sciences.

[76]  J. F. Chen,et al.  Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. , 2006, Arthritis and rheumatism.

[77]  B. Cronstein,et al.  Inflammatory Cytokines Regulate Function and Expression of Adenosine A2A Receptors in Human Monocytic THP-1 Cells1 , 2001, The Journal of Immunology.

[78]  G. Weissmann,et al.  Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[79]  S. B. Kramer,et al.  Adenosine: a physiological modulator of superoxide anion generation by human neutrophils , 1983, The Journal of experimental medicine.